Personalis IncNASDAQ:PSNL
- LAST PRICE3.7400
- TODAY'S CHANGE (%)0.1400 (3.8889%)
- Bid / Lots3.7300/ 4
- Ask / Lots3.7400/ 5
- Open / Previous Close3.6100 / 3.6000
- Day Range
- 52 Week Range
- Volume279,647
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PSNL |
|---|---|---|
| 09:32 ET | 4738 | 3.6791 |
| 09:33 ET | 15043 | 3.66 |
| 09:35 ET | 3000 | 3.66 |
| 09:37 ET | 6900 | 3.6794 |
| 09:39 ET | 4650 | 3.7599 |
| 09:42 ET | 3844 | 3.77 |
| 09:44 ET | 10279 | 3.68 |
| 09:46 ET | 3314 | 3.65 |
| 09:48 ET | 400 | 3.6965 |
| 09:50 ET | 650 | 3.71 |
| 09:51 ET | 200 | 3.715 |
| 09:53 ET | 5265 | 3.64 |
| 09:55 ET | 400 | 3.65 |
| 09:57 ET | 800 | 3.62 |
| 10:00 ET | 3211 | 3.63 |
| 10:02 ET | 4326 | 3.6 |
| 10:04 ET | 1200 | 3.59 |
| 10:06 ET | 2130 | 3.605 |
| 10:08 ET | 200 | 3.59 |
| 10:09 ET | 1500 | 3.605 |
| 10:11 ET | 1854 | 3.59 |
| 10:13 ET | 7765 | 3.63 |
| 10:15 ET | 4018 | 3.66 |
| 10:18 ET | 1000 | 3.63 |
| 10:20 ET | 100 | 3.63 |
| 10:22 ET | 700 | 3.63 |
| 10:24 ET | 1109 | 3.62 |
| 10:26 ET | 2800 | 3.615 |
| 10:27 ET | 400 | 3.61 |
| 10:29 ET | 2149 | 3.615 |
| 10:31 ET | 5653 | 3.63 |
| 10:33 ET | 1494 | 3.6499 |
| 10:36 ET | 307 | 3.6599 |
| 10:38 ET | 713 | 3.64 |
| 10:40 ET | 1953 | 3.65 |
| 10:42 ET | 2230 | 3.625 |
| 10:44 ET | 500 | 3.625 |
| 10:45 ET | 1868 | 3.64 |
| 10:47 ET | 900 | 3.655 |
| 10:49 ET | 1145 | 3.65 |
| 10:51 ET | 2538 | 3.66 |
| 10:54 ET | 800 | 3.655 |
| 10:56 ET | 800 | 3.64 |
| 10:58 ET | 200 | 3.645 |
| 11:00 ET | 1733 | 3.6567 |
| 11:02 ET | 6000 | 3.67 |
| 11:03 ET | 1300 | 3.695 |
| 11:05 ET | 800 | 3.68 |
| 11:07 ET | 800 | 3.665 |
| 11:09 ET | 400 | 3.655 |
| 11:12 ET | 2900 | 3.655 |
| 11:14 ET | 1204 | 3.65 |
| 11:16 ET | 900 | 3.665 |
| 11:18 ET | 952 | 3.665 |
| 11:20 ET | 312 | 3.67 |
| 11:21 ET | 900 | 3.675 |
| 11:23 ET | 100 | 3.675 |
| 11:25 ET | 100 | 3.675 |
| 11:27 ET | 400 | 3.685 |
| 11:30 ET | 200 | 3.67 |
| 11:32 ET | 300 | 3.675 |
| 11:34 ET | 2680 | 3.68 |
| 11:36 ET | 200 | 3.685 |
| 11:38 ET | 400 | 3.69 |
| 11:39 ET | 5800 | 3.695 |
| 11:41 ET | 800 | 3.69 |
| 11:43 ET | 2900 | 3.68 |
| 11:45 ET | 700 | 3.675 |
| 11:48 ET | 2001 | 3.685 |
| 11:50 ET | 300 | 3.68 |
| 11:52 ET | 300 | 3.695 |
| 11:54 ET | 300 | 3.695 |
| 11:56 ET | 400 | 3.71 |
| 11:57 ET | 200 | 3.71 |
| 11:59 ET | 276 | 3.715 |
| 12:01 ET | 6700 | 3.705 |
| 12:03 ET | 6566 | 3.725 |
| 12:06 ET | 12804 | 3.66 |
| 12:08 ET | 1196 | 3.675 |
| 12:10 ET | 700 | 3.685 |
| 12:12 ET | 408 | 3.685 |
| 12:14 ET | 200 | 3.685 |
| 12:15 ET | 875 | 3.695 |
| 12:17 ET | 400 | 3.695 |
| 12:19 ET | 1814 | 3.695 |
| 12:21 ET | 2900 | 3.715 |
| 12:24 ET | 300 | 3.71 |
| 12:26 ET | 404 | 3.705 |
| 12:28 ET | 800 | 3.705 |
| 12:30 ET | 400 | 3.7 |
| 12:32 ET | 700 | 3.71 |
| 12:33 ET | 1514 | 3.705 |
| 12:35 ET | 100 | 3.705 |
| 12:37 ET | 300 | 3.705 |
| 12:39 ET | 1300 | 3.685 |
| 12:42 ET | 506 | 3.68 |
| 12:44 ET | 1000 | 3.685 |
| 12:46 ET | 801 | 3.675 |
| 12:48 ET | 300 | 3.675 |
| 12:50 ET | 1100 | 3.65 |
| 12:51 ET | 300 | 3.655 |
| 12:53 ET | 4101 | 3.67 |
| 12:55 ET | 3100 | 3.6702 |
| 12:57 ET | 200 | 3.675 |
| 01:00 ET | 1500 | 3.6604 |
| 01:02 ET | 700 | 3.655 |
| 01:04 ET | 400 | 3.65 |
| 01:06 ET | 1403 | 3.64 |
| 01:08 ET | 496 | 3.64 |
| 01:09 ET | 600 | 3.63 |
| 01:11 ET | 900 | 3.635 |
| 01:13 ET | 500 | 3.64 |
| 01:15 ET | 300 | 3.645 |
| 01:18 ET | 120 | 3.6401 |
| 01:20 ET | 1208 | 3.645 |
| 01:22 ET | 400 | 3.64 |
| 01:24 ET | 1200 | 3.6391 |
| 01:26 ET | 200 | 3.635 |
| 01:27 ET | 200 | 3.63 |
| 01:29 ET | 696 | 3.625 |
| 01:31 ET | 5049 | 3.66 |
| 01:33 ET | 5447 | 3.675 |
| 01:36 ET | 100 | 3.675 |
| 01:38 ET | 1261 | 3.705 |
| 01:40 ET | 1899 | 3.72 |
| 01:42 ET | 1500 | 3.73 |
| 01:44 ET | 100 | 3.72 |
| 01:45 ET | 2417 | 3.735 |
| 01:47 ET | 100 | 3.73 |
| 01:49 ET | 1629 | 3.74 |
| 01:51 ET | 400 | 3.74 |
| 01:54 ET | 100 | 3.745 |
| 01:58 ET | 100 | 3.745 |
| 02:00 ET | 800 | 3.745 |
| 02:02 ET | 1023 | 3.74 |
Nov 20, 2024
Personalis to Participate at Upcoming Investor Conferences, from 4:01PM ET on Wednesday Nov 20, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 7, 2024
DJ Personalis Price Target Maintained With a $7.25/Share by Needham, from 5:39AM ET on Thursday Nov 07, 2024 by Dow Jones
5:39AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
*DJ Personalis 3Q Loss/Shr 64c >PSNL, from 4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 06, 2024 by Dow JonesPersonalis Reports Third Quarter 2024 Financial Results, from 4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
Personalis to Present at the Stifel 2024 Healthcare Conference, from 4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Personalis Inc | 245.1M | -2.2x | --- |
Editas Medicine Inc | 201.4M | -0.9x | --- |
Poseida Therapeutics Inc | 266.1M | -14.7x | --- |
Fate Therapeutics Inc | 260.8M | -1.6x | --- |
ADC Therapeutics SA | 192.4M | -0.9x | --- |
Enanta Pharmaceuticals Inc | 197.9M | -1.5x | --- |
Company Information
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
Contact Information
- Headquarters
- 6600 Dumbarton CircleFREMONT, CA, United States 94555
- Phone
- 650-752-1300
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board
- Karin Eastham
- President, Chief Executive Officer, Director
- Christopher Hall
- Chief Financial Officer, Chief Operating Officer, Senior Vice President
- Aaron Tachibana
- Executive Vice President - Research and Development, Chief Medical Officer
- Richard Chen
- Senior Vice President, Chief Legal Officer, and Corporate Secretary
- Stephen Moore
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $245.1M |
|---|---|
Revenue (TTM) | $87.5M |
Shares Outstanding | 70.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.88 |
EPS | $-1.68 |
Book Value | $2.56 |
P/E Ratio | -2.2x |
Price/Sales (TTM) | 2.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -84.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
